When the Department of Defense (DoD) announced on Wednesday its intention to implement a mandatory testosterone screening program for service members, the move immediately raised a complex web of questions for experts in men’s health and population-level health interventions. This unprecedented initiative, targeting service members aged 30 and over, carries the potential for significant, yet as yet unforeseen, consequences that demand careful consideration to ensure the well-being of U.S. military personnel.
The decision, reportedly initiated by Defense Secretary Pete Hegseth, marks a departure from standard medical screening protocols and signals a proactive, albeit potentially controversial, approach to a hormone whose role in male health, particularly in aging, has garnered substantial scientific and public interest. As a practicing urologist and a health outcomes researcher with prior experience studying screening tests, including within military populations, the implications of such a widespread program are multifaceted and warrant a thorough examination of both its potential benefits and inherent risks.
The Growing Landscape of Testosterone Therapy
Testosterone, a primary male sex hormone, plays a critical role in the development of male reproductive organs, pubertal changes, and is associated with certain behavioral characteristics, including sex drive. Its levels are intricately regulated by the hypothalamic-pituitary-gonadal (HPG) axis, a complex system involving the brain and body. As men age, a natural decline in testosterone levels is a well-documented phenomenon. This decline can contribute to age-related symptoms such as increased body fat, reduced bone density, and diminished libido.
These age-related physiological changes have fueled a growing interest in testosterone supplementation as a means to mitigate the effects of aging and enhance energy levels in older men. This interest has, in turn, driven a significant expansion of the global testosterone therapy market. In the late 1980s, global sales were a modest $18 million annually. By 2025, projections indicate this figure will soar to nearly $2 billion. This dramatic growth has been significantly influenced by direct-to-consumer marketing, burgeoning online prescribing platforms, wellness communities, and the endorsements of online influencers. While many individuals utilizing these therapies receive appropriate medical guidance, a concerning trend has emerged where some obtain testosterone through less regulated online channels, sometimes resulting in dangerously elevated levels far exceeding normal or safe parameters.
Understanding the Risks and Benefits: A Complex Equation
Testosterone replacement therapy (TRT) is known to have potential benefits, including increased muscle mass, enhanced libido, and in some cases, improvements in mood and behavior that can be perceived positively by recipients. However, the medical community’s understanding of the long-term implications of TRT, particularly in populations without clearly defined hypogonadism, is still evolving.
Crucially, TRT is not without significant risks. Early research, such as the 2010 Testosterone in Older Men with Mobility Limitations (TOM) study, was halted prematurely due to an observed higher incidence of major cardiac events, including heart attacks and strokes, among participants receiving TRT. While a more recent study, the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial published in 2023, did not replicate the increased cardiac event risk and found TRT to be no worse than placebo in that regard, it did identify a higher incidence of acute kidney injury, atrial fibrillation, and pulmonary embolism in those undergoing testosterone therapy.
Furthermore, research involving military beneficiaries covered by TRICARE, the DoD’s health insurance program, has shed light on specific side effects within this demographic. Studies supported by the DoD have indicated higher rates of kidney stones and obstructive sleep apnea among military personnel using testosterone supplementation. While one of these studies also noted a significant improvement in cardiovascular disease outcomes, the findings underscore the nuanced and potentially variable impact of TRT.
Specific Concerns for Younger Service Members
A critical aspect of the DoD’s announcement is its focus on service members aged 30 and over. For this age group, and particularly for those considering starting a family, the impact of TRT on fertility is a significant concern. Testosterone replacement therapy can lead to a reduction in testicular size and sperm count, a consequence that both the American Urological Association and the Endocrine Society guidelines highlight, advising against TRT for men intending to father children.
Navigating the Diagnostic and Treatment Labyrinth
The accurate diagnosis of low testosterone levels is a complex process that requires careful consideration of multiple factors. Testosterone measurements are susceptible to confounding variables and necessitate specific timing—typically in the morning—along with a confirmatory second test. Moreover, these readings must be interpreted alongside other biological markers, including blood counts and other hormone levels, to confirm a diagnosis and identify potential underlying causes.
Before initiating TRT, individuals should undergo comprehensive screening for conditions that could be exacerbated by the therapy. This includes assessing for sleep apnea, a high risk for prostate cancer, existing heart conditions, heart failure, or symptoms of thrombophilia (an abnormally high concentration of red blood cells).
Once a TRT protocol is initiated, ongoing monitoring is essential. This monitoring serves a dual purpose: to ensure the treatment is effective and to detect any adverse side effects. Current Endocrine Society guidelines recommend against routine population-level screening for hypogonadism in asymptomatic men and advise against routine supplementation for younger men with low testosterone levels, recommendations that appear to diverge from the DoD’s new directive.
Implications of a Mandatory Screening Program
The DoD’s decision to implement a mandatory screening program for service members aged 30 and over represents a significant undertaking with far-reaching implications. Secretary Hegseth’s statement that the decision to pursue supplementation would rest with individual service members, should their testosterone levels be found to be low, emphasizes the need for robust and personalized patient counseling. Service members must receive thorough education regarding the potential risks and benefits of TRT, tailored to their individual physiology, preferences, and health status.
The logistical challenge of implementing personalized monitoring on the scale required for the entire Department of Defense health system cannot be overstated. However, it is a critical component for ensuring the safe and responsible execution of this initiative. Without adequate personalized monitoring, the program risks creating more health problems than it solves.
This widespread, mandatory testing program for U.S. servicemembers is a novel undertaking in the realm of population-level health interventions, lacking clear precedent in this specific medical context. For the health and welfare of military personnel, it is imperative that this testing initiative is accompanied by rigorous, individualized patient monitoring and comprehensive population-level surveillance. Only through such careful oversight can the program be assured of being implemented safely and appropriately, minimizing unintended consequences and maximizing potential benefits. The success of this program will hinge not just on the act of testing, but on the commitment to comprehensive care and informed decision-making for every service member involved.
Alexander Cole, M.D., is a board-certified urologist.
STAT News’s coverage of health challenges facing men and boys is supported by Rise Together, a donor-advised fund sponsored and administered by National Philanthropic Trust and established by Richard Reeves, founding president of the American Institute for Boys and Men; and by the Boston Foundation. The financial supporters of STAT News are not involved in any decisions about its journalism.
